JP2009532497A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009532497A5 JP2009532497A5 JP2009504434A JP2009504434A JP2009532497A5 JP 2009532497 A5 JP2009532497 A5 JP 2009532497A5 JP 2009504434 A JP2009504434 A JP 2009504434A JP 2009504434 A JP2009504434 A JP 2009504434A JP 2009532497 A5 JP2009532497 A5 JP 2009532497A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- inhibitors
- kinase
- tyrosine kinase
- kinase inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 claims description 70
- 150000001875 compounds Chemical class 0.000 claims description 42
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 38
- 108091008605 VEGF receptors Proteins 0.000 claims description 20
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 20
- 230000002401 inhibitory effect Effects 0.000 claims description 20
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims description 16
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims description 16
- 239000013543 active substance Substances 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 102000003923 Protein Kinase C Human genes 0.000 claims description 10
- 108090000315 Protein Kinase C Proteins 0.000 claims description 10
- 230000000340 anti-metabolite Effects 0.000 claims description 10
- 229940100197 antimetabolite Drugs 0.000 claims description 10
- 239000002256 antimetabolite Substances 0.000 claims description 10
- 230000007423 decrease Effects 0.000 claims description 10
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 10
- 150000003431 steroids Chemical class 0.000 claims description 10
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 claims description 7
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 7
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims description 6
- 229940124647 MEK inhibitor Drugs 0.000 claims description 6
- 229960002436 cladribine Drugs 0.000 claims description 6
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 claims description 6
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 6
- 229960005420 etoposide Drugs 0.000 claims description 6
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims description 6
- 229960000961 floxuridine Drugs 0.000 claims description 6
- 229940080818 propionamide Drugs 0.000 claims description 6
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 claims description 6
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 claims description 6
- IAHFWCOBPZCAEA-UHFFFAOYSA-N succinonitrile Chemical compound N#CCCC#N IAHFWCOBPZCAEA-UHFFFAOYSA-N 0.000 claims description 6
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 6
- 229960001278 teniposide Drugs 0.000 claims description 6
- 229940076850 Tyrosine phosphatase inhibitor Drugs 0.000 claims description 5
- 230000037361 pathway Effects 0.000 claims description 5
- 239000003934 phosphoprotein phosphatase inhibitor Substances 0.000 claims description 5
- ODYLTZRECSDWCJ-UHFFFAOYSA-N 6-(2-phenylethyl)-1,2,3,3a,4,5,7,7a-octahydropyrrolo[2,3-c]pyridine Chemical compound C1CC2CCNC2CN1CCC1=CC=CC=C1 ODYLTZRECSDWCJ-UHFFFAOYSA-N 0.000 claims description 2
- 229940043355 kinase inhibitor Drugs 0.000 claims 36
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 36
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 32
- 238000000034 method Methods 0.000 claims 20
- 201000010099 disease Diseases 0.000 claims 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 18
- 230000002062 proliferating effect Effects 0.000 claims 18
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 16
- 229910052799 carbon Inorganic materials 0.000 claims 14
- 125000004432 carbon atom Chemical group C* 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 14
- 239000003795 chemical substances by application Substances 0.000 claims 13
- 235000018102 proteins Nutrition 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 11
- -1 di-substituted amino Chemical group 0.000 claims 9
- 108020004414 DNA Proteins 0.000 claims 8
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 claims 8
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 claims 8
- 102000003964 Histone deacetylase Human genes 0.000 claims 8
- 108090000353 Histone deacetylase Proteins 0.000 claims 8
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims 8
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 claims 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 8
- 206010033128 Ovarian cancer Diseases 0.000 claims 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 8
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 8
- 230000001640 apoptogenic effect Effects 0.000 claims 8
- 230000015572 biosynthetic process Effects 0.000 claims 8
- 201000005296 lung carcinoma Diseases 0.000 claims 8
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 claims 8
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 claims 8
- 201000001441 melanoma Diseases 0.000 claims 8
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims 8
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 7
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 239000001301 oxygen Substances 0.000 claims 7
- 125000000547 substituted alkyl group Chemical group 0.000 claims 7
- 229910052717 sulfur Inorganic materials 0.000 claims 7
- 239000011593 sulfur Substances 0.000 claims 7
- 125000004965 chloroalkyl group Chemical group 0.000 claims 6
- 239000002552 dosage form Substances 0.000 claims 6
- 229940123877 Aurora kinase inhibitor Drugs 0.000 claims 4
- 229940126074 CDK kinase inhibitor Drugs 0.000 claims 4
- 229940043709 CaM kinase II inhibitor Drugs 0.000 claims 4
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 claims 4
- 229940122204 Cyclooxygenase inhibitor Drugs 0.000 claims 4
- 102000053602 DNA Human genes 0.000 claims 4
- 101100181139 Drosophila melanogaster Pkcdelta gene Proteins 0.000 claims 4
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 4
- 101800003838 Epidermal growth factor Proteins 0.000 claims 4
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 claims 4
- 101100457333 Homo sapiens MAPK11 gene Proteins 0.000 claims 4
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 4
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 claims 4
- 229940113306 Ligase inhibitor Drugs 0.000 claims 4
- 229940083338 MDM2 inhibitor Drugs 0.000 claims 4
- 239000012819 MDM2-Inhibitor Substances 0.000 claims 4
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims 4
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims 4
- 102100028905 Megakaryocyte-associated tyrosine-protein kinase Human genes 0.000 claims 4
- 102000029749 Microtubule Human genes 0.000 claims 4
- 108091022875 Microtubule Proteins 0.000 claims 4
- 108700036166 Mitogen-Activated Protein Kinase 11 Proteins 0.000 claims 4
- 102100026929 Mitogen-activated protein kinase 11 Human genes 0.000 claims 4
- 101100523539 Mus musculus Raf1 gene Proteins 0.000 claims 4
- 108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 claims 4
- 102100039337 NF-kappa-B inhibitor alpha Human genes 0.000 claims 4
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 claims 4
- 229940122907 Phosphatase inhibitor Drugs 0.000 claims 4
- 108091008611 Protein Kinase B Proteins 0.000 claims 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 4
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims 4
- 102000009572 RNA Polymerase II Human genes 0.000 claims 4
- 108010009460 RNA Polymerase II Proteins 0.000 claims 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 4
- 101150046814 SAPK2 gene Proteins 0.000 claims 4
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 claims 4
- 229930182558 Sterol Natural products 0.000 claims 4
- 108010016672 Syk Kinase Proteins 0.000 claims 4
- 102000000551 Syk Kinase Human genes 0.000 claims 4
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 claims 4
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims 4
- 101710112791 Tyrosine-protein kinase JAK2 Proteins 0.000 claims 4
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 claims 4
- 101710112792 Tyrosine-protein kinase JAK3 Proteins 0.000 claims 4
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims 4
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims 4
- 229940123429 VEGFR tyrosine kinase inhibitor Drugs 0.000 claims 4
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 claims 4
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 4
- 239000003121 adenosine kinase inhibitor Substances 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 4
- 230000001780 adrenocortical effect Effects 0.000 claims 4
- 239000002168 alkylating agent Substances 0.000 claims 4
- 229940100198 alkylating agent Drugs 0.000 claims 4
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 4
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 4
- 230000002280 anti-androgenic effect Effects 0.000 claims 4
- 229940046836 anti-estrogen Drugs 0.000 claims 4
- 230000001833 anti-estrogenic effect Effects 0.000 claims 4
- 239000000051 antiandrogen Substances 0.000 claims 4
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 claims 4
- 230000006907 apoptotic process Effects 0.000 claims 4
- 239000003719 aurora kinase inhibitor Substances 0.000 claims 4
- 239000011230 binding agent Substances 0.000 claims 4
- 229940046731 calcineurin inhibitors Drugs 0.000 claims 4
- 108010046616 cdc25 Phosphatases Proteins 0.000 claims 4
- 102000007588 cdc25 Phosphatases Human genes 0.000 claims 4
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims 4
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims 4
- 239000002852 cysteine proteinase inhibitor Substances 0.000 claims 4
- 230000002124 endocrine Effects 0.000 claims 4
- 229940116977 epidermal growth factor Drugs 0.000 claims 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 4
- 239000000328 estrogen antagonist Substances 0.000 claims 4
- 229940045109 genistein Drugs 0.000 claims 4
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims 4
- 235000006539 genistein Nutrition 0.000 claims 4
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims 4
- 229940088597 hormone Drugs 0.000 claims 4
- 239000005556 hormone Substances 0.000 claims 4
- 239000000411 inducer Substances 0.000 claims 4
- 238000003780 insertion Methods 0.000 claims 4
- 230000037431 insertion Effects 0.000 claims 4
- 108010042209 insulin receptor tyrosine kinase Proteins 0.000 claims 4
- 239000000436 ligase inhibitor Substances 0.000 claims 4
- 239000000463 material Substances 0.000 claims 4
- 210000004688 microtubule Anatomy 0.000 claims 4
- 239000003226 mitogen Substances 0.000 claims 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 4
- GTVPOLSIJWJJNY-UHFFFAOYSA-N olomoucine Chemical compound N1=C(NCCO)N=C2N(C)C=NC2=C1NCC1=CC=CC=C1 GTVPOLSIJWJJNY-UHFFFAOYSA-N 0.000 claims 4
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 claims 4
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims 4
- 229910052697 platinum Inorganic materials 0.000 claims 4
- 229920000768 polyamine Polymers 0.000 claims 4
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 claims 4
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 claims 4
- 239000003801 protein tyrosine phosphatase 1B inhibitor Substances 0.000 claims 4
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 claims 4
- 230000001105 regulatory effect Effects 0.000 claims 4
- 108010087686 src-Family Kinases Proteins 0.000 claims 4
- 102000009076 src-Family Kinases Human genes 0.000 claims 4
- 150000003432 sterols Chemical class 0.000 claims 4
- 235000003702 sterols Nutrition 0.000 claims 4
- 238000003786 synthesis reaction Methods 0.000 claims 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 101710113864 Heat shock protein 90 Proteins 0.000 description 4
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 4
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 4
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical class N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 4
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 4
- 108091006112 ATPases Proteins 0.000 description 3
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 3
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 3
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 108091007065 BIRCs Proteins 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 2
- 229960004169 mitoxantrone hydrochloride Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- OGBVRMYSNSKIEF-UHFFFAOYSA-N Benzylphosphonic acid Chemical compound OP(O)(=O)CC1=CC=CC=C1 OGBVRMYSNSKIEF-UHFFFAOYSA-N 0.000 description 1
- 101000611262 Caenorhabditis elegans Probable protein phosphatase 2C T23F11.1 Proteins 0.000 description 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 102100024025 Heparanase Human genes 0.000 description 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 description 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
- 101000688229 Leishmania chagasi Protein phosphatase 2C Proteins 0.000 description 1
- 102000014750 Phosphorylase Kinase Human genes 0.000 description 1
- 108010064071 Phosphorylase Kinase Proteins 0.000 description 1
- 229940116193 Protein phosphatase inhibitor Drugs 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- VIHAEDVKXSOUAT-UHFFFAOYSA-N but-2-en-4-olide Chemical compound O=C1OCC=C1 VIHAEDVKXSOUAT-UHFFFAOYSA-N 0.000 description 1
- DHZBEENLJMYSHQ-XCVPVQRUSA-N cantharidin Chemical compound C([C@@H]1O2)C[C@@H]2[C@]2(C)[C@@]1(C)C(=O)OC2=O DHZBEENLJMYSHQ-XCVPVQRUSA-N 0.000 description 1
- 229940095758 cantharidin Drugs 0.000 description 1
- 229930008397 cantharidin Natural products 0.000 description 1
- DHZBEENLJMYSHQ-UHFFFAOYSA-N cantharidine Natural products O1C2CCC1C1(C)C2(C)C(=O)OC1=O DHZBEENLJMYSHQ-UHFFFAOYSA-N 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 108010037536 heparanase Proteins 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- VYGYNVZNSSTDLJ-HKCOAVLJSA-N monorden Natural products CC1CC2OC2C=C/C=C/C(=O)CC3C(C(=CC(=C3Cl)O)O)C(=O)O1 VYGYNVZNSSTDLJ-HKCOAVLJSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- AECPBJMOGBFQDN-YMYQVXQQSA-N radicicol Chemical compound C1CCCC(=O)C[C@H]2[C@H](Cl)C(=O)CC(=O)[C@H]2C(=O)O[C@H](C)C[C@H]2O[C@@H]21 AECPBJMOGBFQDN-YMYQVXQQSA-N 0.000 description 1
- 229930192524 radicicol Natural products 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78940106P | 2006-04-05 | 2006-04-05 | |
| PCT/US2007/065911 WO2007115286A2 (en) | 2006-04-05 | 2007-04-04 | Combinations of therapeutic agents for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009532497A JP2009532497A (ja) | 2009-09-10 |
| JP2009532497A5 true JP2009532497A5 (enExample) | 2010-05-20 |
Family
ID=38564304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009504434A Pending JP2009532497A (ja) | 2006-04-05 | 2007-04-04 | 癌を処置するための治療剤の組合せ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20090099103A1 (enExample) |
| EP (1) | EP2004165A2 (enExample) |
| JP (1) | JP2009532497A (enExample) |
| KR (1) | KR20080108516A (enExample) |
| CN (1) | CN101415411A (enExample) |
| AU (1) | AU2007234379A1 (enExample) |
| BR (1) | BRPI0710291A2 (enExample) |
| CA (1) | CA2645242A1 (enExample) |
| MX (1) | MX2008012716A (enExample) |
| RU (1) | RU2008143554A (enExample) |
| WO (1) | WO2007115286A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2454118B (en) | 2007-06-06 | 2010-06-02 | Univ Maryland | Hdac inhibitors and hormone targeted drugs for the treatment of cancer |
| AR077975A1 (es) | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
| SG10201600077RA (en) | 2011-01-11 | 2016-02-26 | Glaxosmithkline Llc | Combination |
| RU2622015C2 (ru) | 2011-11-11 | 2017-06-08 | Новартис Аг | Способ лечения пролиферативного заболевания |
| MX2016004265A (es) * | 2013-10-01 | 2016-07-08 | Novartis Ag | Combinacion. |
| CN120577536A (zh) * | 2024-02-21 | 2025-09-02 | 上海交通大学医学院附属仁济医院 | 转运蛋白abca8阳性癌症相关成纤维细胞在制备诊断试剂盒中的用途及转运蛋白abca8在药物筛选中的用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0119249D0 (en) * | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
| MXPA04006822A (es) * | 2002-01-14 | 2004-12-08 | Novartis Ag | Combinaciones que comprenden epotilonas y anti-metabolitos. |
| MXPA05012464A (es) * | 2003-05-21 | 2006-01-30 | Novartis Ag | Combinacion de inhibidores de deacetilasa de histona con agentes quimioterapeuticos. |
| CA2536140A1 (en) * | 2003-08-18 | 2005-02-24 | Pfizer Products Inc. | Dosing schedule for erbb2 anticancer agents |
| DK2253614T3 (da) * | 2004-04-07 | 2013-01-07 | Novartis Ag | IAP-inhibitorer |
| WO2006030947A1 (ja) * | 2004-09-13 | 2006-03-23 | Eisai R & D Management Co., Ltd. | スルホンアミド含有化合物の血管新生阻害物質との併用 |
| US20060148772A1 (en) * | 2004-11-16 | 2006-07-06 | Evans Astrid H | Combination |
| CN101080227B (zh) * | 2004-12-15 | 2011-08-31 | 诺瓦提斯公司 | 用于治疗癌症的治疗剂的组合 |
-
2007
- 2007-04-04 KR KR1020087024228A patent/KR20080108516A/ko not_active Withdrawn
- 2007-04-04 RU RU2008143554/15A patent/RU2008143554A/ru not_active Application Discontinuation
- 2007-04-04 BR BRPI0710291-7A patent/BRPI0710291A2/pt not_active IP Right Cessation
- 2007-04-04 CN CNA2007800121108A patent/CN101415411A/zh active Pending
- 2007-04-04 MX MX2008012716A patent/MX2008012716A/es not_active Application Discontinuation
- 2007-04-04 CA CA002645242A patent/CA2645242A1/en not_active Abandoned
- 2007-04-04 US US12/282,525 patent/US20090099103A1/en not_active Abandoned
- 2007-04-04 AU AU2007234379A patent/AU2007234379A1/en not_active Abandoned
- 2007-04-04 EP EP07781283A patent/EP2004165A2/en not_active Withdrawn
- 2007-04-04 JP JP2009504434A patent/JP2009532497A/ja active Pending
- 2007-04-04 WO PCT/US2007/065911 patent/WO2007115286A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009536153A5 (enExample) | ||
| EP2709990B1 (en) | 1-((3-((1-Piperazinyl)carbonyl)phenyl)methyl)-2,4(1H,3H)-quinazolinedione derivatives as PARP inhibitors for treating cancer | |
| EP1948242B1 (en) | Cytotoxic compounds | |
| JP2009532497A5 (enExample) | ||
| US6528513B2 (en) | Pyrimidine derivatives | |
| US10023572B2 (en) | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof | |
| JP2009532503A5 (enExample) | ||
| US10350199B2 (en) | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof | |
| US20100010025A1 (en) | Pyrimidine Derivatives | |
| EP1853602B1 (en) | Chemical compounds | |
| FI117673B (fi) | Nukleosidimonofosfaattijohdannaiset, niiden valmistus ja käyttö immuunivastetta heikentävien lääkkeiden valmistukseen | |
| US8129403B2 (en) | Chemical compounds | |
| EP1246623B1 (en) | Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof | |
| EP2383262B1 (en) | Phenyl pyrimidone compounds, pharmaceutical compositions, preparation methods and uses thereof | |
| EP1450811B1 (en) | Compounds specific to adenosine A1 and A3 receptors and uses thereof | |
| WO2016040182A1 (en) | 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof | |
| HU228196B1 (en) | 2-phenyl substituted imidazotriazinones, process for their preparation and pharmaceutical compositions thereof | |
| CZ256795A3 (en) | Derivatives of cycloalkanoindole and cyclalkanoazaindole, process of their preparation, pharmaceutical compositions containing thereof and their use | |
| PL181893B1 (pl) | Zwiazki bedace pochodnymi pirymidyny i naftyrydyny oraz preparat farmaceutyczny zawierajacy je PL PL PL | |
| US20110269808A1 (en) | Compositions comprising (s)-2-amino-1-(4-chlorophenyl)-1-[4-(1h-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases | |
| CN112689634B (zh) | Smad3抑制剂 | |
| US20090233948A1 (en) | Inhibitors of nucleoside phosphorylases and nucleosidases | |
| EP3248979A1 (en) | Novel inhibitor of flt3 kinase and use thereof | |
| EP2041119B1 (fr) | Derives de pyrazolylbenzimidazole, compositions les contenant et leur utilisation | |
| JPH0219363A (ja) | イミダゾリジン誘導体 |